In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-2 Lateral Articulation in Posterior Atlantoaxial Fusion in Adult Patients with or Without Conventional Structural Bone Graft

    Final Number:
    1662

    Authors:
    Seba Ramhmdani M.D.; Wataru Ishida MD; Yuanxuan Xia BA; Risheng Xu AB AM MD PhD; Thomas Kosztowski BS; John Choi BS, MEd; Rafael De la Garza Ramos MD; Benjamin D. Elder MD, PhD; Ziya L. Gokaslan MD; Nicholas Theodore MD; Jean-Paul Wolinsky MD; Daniel M. Sciubba MD; Timothy F. Witham BS MD; Ali Bydon MD; Sheng-fu Larry Lo MD, MHSc

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction as well as the upper cervical region. Although the potential advantages of rhBMP-2 over autograft and/or allograft alone are well-documented in the lumbar spine, its indication in posterior atlantoaxial fusion has not been well-characterized. In our institution, for selected adult cases of posterior atlantoaxial fusion, we apply rhBMP-2 to the C1-2 joint, either (A) alone or with hydroxyapatite and/or locally harvested autograft chips, or (B) with conventional structural autogenic/allogenic bone graft (SAABG). Here, we will compare clinical outcomes of the two groups with special attention to their fusion rates to elucidate feasibility of the techniques.

    Methods: Single-center, retrospective data review from 2008 to 2014 identified 58 patients who underwent posterior atlantoaxial fusion with rhBMP-2: (A) 34 patients without SAABG and (B) 24 patients with SAABG. Clinical records of these 58 patients were collected and statistically analyzed. P values <.05 were regarded as statistically significant.

    Results: Baseline characteristics such as age, sex, BMI, and smoking status, no statistically significant differences were identified. The overall fusion rate was 94.8% (55/58), which was comparable to other conventional techniques documented in the literature. The (A) group had significantly shorter operative time (p=0.03) and less estimated blood loss than the (B) group (p=0.003). Long-term complication rates were similar between the two groups: one-year C1-2 instability/pseudoarthrosis rate, (A)5.8% versus (B)4.2%, p=1; one-year instrumentation failure rate, (A)8.8% versus (B)12.5%, p=0.68; one-year revision surgery rate, (A)8.8% versus (B)16.7%. p=0.43.

    Conclusions: Albeit retrospective, single-center nature of the study, it was demonstrated that the use of rhBMP-2 at the C1-2 joint without conventional SAABG was a safe, reasonable alternative with the long-term outcomes comparable to rhBMP-2 with SAABG or historical controls in the literature.

    Patient Care: Use of rhBMP-2 with or without structual allo/autogenic bone graft resulted in acceptable clinical outcomes in patients deemed to have a relatively higher risk of C1-2 pseudoarthrosis, and thus be beneficial to them, potentially reducing operative time and blood loss.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of ..., 2) Discuss, in small groups

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy